A New Dawn for IgA Nephropathy –
Redefining What is Possible with Sparsentan
Objectives
In this webinar we:
- Described the draft Kidney Disease: Improving Global Outcomes (KDIGO) criteria for risk of disease progression in IgA nephropathy, the proposed target proteinuria levels for preserving kidney function, and the scientific rationale for these proposed proteinuria targets
- Described the clinical benefits of achieving proteinuria remission and how sparsentan may help clinicians achieve these targets
- Evaluated the use of sparsentan in the evolving IgA nephropathy therapeutic landscape in order to better patient outcomes
Browse our collection of related resources
Long-Term Outcomes in IgA Nephropathy
Authors: David Pitcher, Fiona Braddon, Bruce Hendry et al.
Type: Publication
Efficacy and Safety of Sparsentan Versus Irbesartan in Patients With IgA Nephropathy (PROTECT): 2-year Results From a Randomised, Active-Controlled, Phase 3 Trial
Authors: Brad Rovin, Jonathan Barratt, Hiddo JL Heerspink et al.
Type: Publication
Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT
Speakers: Hiddo JL. Heerspink, Vladimir Tesar, Radko Komers, Bruce M. Hendry, Priscila Preciado, Edward Murphy, Brad H. Rovin on behalf of the DUPRO Steering Committee and PROTECT investigators
Type: Poster
PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g/g
Speakers: Laura Kooienga, Hernán Trimarchi, Jürgen Floege, Priscila Preciado, Edward Murphy, Jai Radhakrishnan
Type: Presentation
Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy (IgAN): Interim Analysis of the SPARTAN Trial
Speakers: Chee Kay Cheung, Stephanie Moody, Neeraj Dhaun, Siân Griffin, Alexandra Howson, Radko Komers, Alex Mercer, Matthew Sayer, Smeeta Sinha, Lisa Willcocks, Jonathan Barratt
Type: Presentation
MA-SP-25-0013 | March 2025